bioRxivNeurosciencePreprint
Incomplete cerebellar circuit restoration limits functional recovery following SMN therapy in severe spinal muscular atrophy
Sayan Ruwald, Adela Vankova, Frieda Hanschmann, Christian Menedo, Sandra Wittig, Marie L Stephan, Vanessa Dreilich, Severine Ruetze, Amy K. SmithiD, Leonie Sowoidnich, Christian GeisiD, Stefan HallermanniD, Charlotte J. SumneriD, Livio PellizzoniiD, Beatriz Blanco-RedondoiD, Florian GerstneriD, Christian M. SimoniD
Abstract
Spinal muscular atrophy (SMA) is caused by a deficiency in the survival motor neuron (SMN) protein, resulting in degeneration of spinal motor neurons (MNs). However, persistent neurological deficits despite postnatal SMN-restoring therapies suggest that recovery of sensorimotor and supraspinal circuits may be incomplete. The cerebellum has recently emerged as a supraspinal contributor to motor deficits in the severe SMN{Delta}7 mouse model, yet it remains unclear whether cerebellar pathology is a conserved and therapeutically reversible feature across severe SMA mouse models and clinical subtypes. Here, we identify cerebellar pathology in Taiwanese SMA mice, characterized by hypoplasia, disrupted organization and loss of Purkinje cells (PCs), altered synaptic circuitry, and impaired cerebellar cortical output. Unlike the previously described p53-dependent PC degeneration in SMN{Delta}7 mice, cerebellar pathology in Taiwanese SMA mice was associated with developmental disorganization and external granule layer (EGL)-restricted p53 activation. Human cerebellar tissue mirrored this distinction, with p53 activation found in PCs from SMA Type I and in the EGL from SMA Type 0 individuals, indicating that cerebellar pathology arises through distinct mechanisms across severe forms of SMA. Importantly, two SMN-restoring strategies produced divergent therapeutic outcomes. In SMN{Delta}7 mice, AAV9-SMN prevented PC degeneration yet incompletely restored cerebellar circuitry. AAV9-SMN-treated Taiwanese mice developed severe ataxia-like deficits, retained profound cerebellar pathology, and survived to approximately one month of age. In contrast, systemic risdiplam rescued cerebellar pathology, motor behavior, and survival in both models. Together, these findings identify cerebellar pathology as a conserved yet distinct feature across severe forms of SMA and reveal cell type-specific tropism as a critical determinant of therapeutic outcome. More broadly, these findings suggest that successful recovery requires restoration of distributed supraspinal circuit integrity in addition to rescue of spinal motor pathways.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Central and peripheral delivery of AAV9-SMN target different pathomechanisms in a mouse model of spinal muscular atrophy
Aoife Reilly, Marc‐Olivier Deguise, … Rashmi Kothary·bioRxiv·Nov 8, 2021
- Stasimon contributes to the loss of sensory synapses and motor neuron death in a mouse model of spinal muscular atrophy
Christian M. Simon, Meaghan Van Alstyne, … Livio Pellizzoni·Cell ReportsPeer-reviewed·Jan 1, 2019
- SMN deficiency induces an early non-atrophic myopathy with alterations in the contractile and excitatory coupling machinery of skeletal myofibers in the SMN{triangleup}7 mouse model of spinal muscular atrophy
Maria Teresa Berciano, Alaó Gatius, … Olga Tapia·International Journal of Molecular SciencesPeer-reviewed·Nov 19, 2024
- A chemical screen identifies p38 MAPK inhibition as a candidate neuroprotective strategy for combinatorial SMA therapy
Maria Jose Carlini, Jorge Espinoza‐Derout, … Livio Pellizzoni·bioRxiv·Mar 6, 2025
- Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn 2B/- mouse model of SMA
Maria Jose Carlini, Marina K Triplett, Livio Pellizzoni·PLoS ONEPeer-reviewed·Aug 1, 2022
- SMA Type II Skeletal Muscle Treated with Nusinersen shows SMN Restoration but Mitochondrial Deficiency.
Fiorella Carla Grandi, Stéphanie Astord, … Piera Smeriglio·bioRxiv·Feb 29, 2024